Early-stage development is a fast-paced phase in the life cycle of gene therapy product development. For adeno-associated viral vectors, this phase comes with modality specific challenges including limited available material and serotype-specific biophysical properties that impact the process development strategies.
High throughput technology makes a significant impact in AAV process development because it helps circumvent modality specific challenges. This presentation highlights utilization of high throughout purification platforms for AAVs which enables accelerated process development and product quality understanding.